Early-phase drug discovery of β-III-spectrin actin-binding modulators for treatment of spinocerebellar ataxia type 5

[1]  T. Hays,et al.  β-III-spectrin N-terminus is required for high-affinity actin binding and SCA5 neurotoxicity , 2022, Scientific reports.

[2]  David D. Thomas,et al.  Cardiac myosin-binding protein C interaction with actin is inhibited by compounds identified in a high-throughput fluorescence lifetime screen , 2021, The Journal of biological chemistry.

[3]  David D. Thomas,et al.  Novel drug discovery platform for spinocerebellar ataxia, using fluorescence technology targeting β-III-spectrin , 2020, The Journal of biological chemistry.

[4]  Junko Kurisu,et al.  βIII spectrin controls the planarity of Purkinje cell dendrites by modulating perpendicular axon-dendrite interactions , 2020, Development.

[5]  Tory M. Schaaf,et al.  Live-Cell Cardiac-Specific High-Throughput Screening Platform for Drug-Like Molecules That Enhance Ca2+ Transport , 2020, Cells.

[6]  M. Chorilli,et al.  Biological Properties and Analytical Methods for Micafungin: A Critical Review , 2020, Critical reviews in analytical chemistry.

[7]  D. Bers,et al.  RyR1-targeted drug discovery pipeline integrating FRET-based high-throughput screening and human myofiber dynamic Ca2+ assays , 2020, Scientific Reports.

[8]  K. Ashe,et al.  Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies , 2019, Alzheimer's & Dementia.

[9]  Tory M. Schaaf,et al.  Noncompetitive inhibitors of TNFR1 probe conformational activation states , 2019, Science Signaling.

[10]  E. Bertini,et al.  Heterozygous missense variants of SPTBN2 are a frequent cause of congenital cerebellar ataxia , 2019, Clinical genetics.

[11]  Tory M. Schaaf,et al.  Red-Shifted FRET Biosensors for High-Throughput Fluorescence Lifetime Screening , 2018, Biosensors.

[12]  Tory M. Schaaf,et al.  Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells , 2018, Scientific Reports.

[13]  David D. Thomas,et al.  High-throughput screen, using time-resolved FRET, yields actin-binding compounds that modulate actin–myosin structure and function , 2018, The Journal of Biological Chemistry.

[14]  Lifang Peng,et al.  Ginsenoside Rb1 confers neuroprotection via promotion of glutamate transporters in a mouse model of Parkinson's disease , 2018, Neuropharmacology.

[15]  E. Egelman,et al.  Structural basis for high-affinity actin binding revealed by a β-III-spectrin SCA5 missense mutation , 2017, Nature Communications.

[16]  David D. Thomas,et al.  β-III-spectrin spinocerebellar ataxia type 5 mutation reveals a dominant cytoskeletal mechanism that underlies dendritic arborization , 2017, Proceedings of the National Academy of Sciences.

[17]  C. Knibbe,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Micafungin , 2017, Clinical Pharmacokinetics.

[18]  Tory M. Schaaf,et al.  An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors , 2017, SLAS discovery : advancing life sciences R & D.

[19]  Tory M. Schaaf,et al.  Spectral Unmixing Plate Reader: High-Throughput, High-Precision FRET Assays in Living Cells , 2017, SLAS discovery : advancing life sciences R & D.

[20]  D. Bers,et al.  High-Throughput Screens to Discover Small-Molecule Modulators of Ryanodine Receptor Calcium Release Channels , 2017, SLAS discovery : advancing life sciences R & D.

[21]  Tory M. Schaaf,et al.  High-Throughput Spectral and Lifetime-Based FRET Screening in Living Cells to Identify Small-Molecule Effectors of SERCA , 2016, SLAS discovery : advancing life sciences R & D.

[22]  J. Rothstein,et al.  Posterior cerebellar Purkinje cells in an SCA5/SPARCA1 mouse model are especially vulnerable to the synergistic effect of loss of β-III spectrin and GLAST , 2016, Human molecular genetics.

[23]  W. Setzer,et al.  Ginsenoside Rb1 as a neuroprotective agent: A review , 2016, Brain Research Bulletin.

[24]  David D. Thomas,et al.  A human β-III-spectrin spinocerebellar ataxia type 5 mutation causes high-affinity F-actin binding , 2016, Scientific Reports.

[25]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[26]  David D. Thomas,et al.  Amplitude of the actomyosin power stroke depends strongly on the isoform of the myosin essential light chain , 2015, Proceedings of the National Academy of Sciences.

[27]  Gang Chen,et al.  Mutant β-III Spectrin Causes mGluR1α Mislocalization and Functional Deficits in a Mouse Model of Spinocerebellar Ataxia Type 5 , 2014, The Journal of Neuroscience.

[28]  Tory M. Schaaf,et al.  Discovery of Enzyme Modulators via High-Throughput Time-Resolved FRET in Living Cells , 2014, Journal of biomolecular screening.

[29]  P. Troke,et al.  Tissue Penetration of Antifungal Agents , 2014, Clinical Microbiology Reviews.

[30]  J. Rothstein,et al.  β-III Spectrin Is Critical for Development of Purkinje Cell Dendritic Tree and Spine Morphogenesis , 2011, The Journal of Neuroscience.

[31]  Robert H. Brown,et al.  Mutations in the N-terminal actin-binding domain of filamin C cause a distal myopathy. , 2011, American journal of human genetics.

[32]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[33]  Alexander Kyrychenko,et al.  High-performance time-resolved fluorescence by direct waveform recording. , 2010, The Review of scientific instruments.

[34]  A. Lyndon,et al.  Beta-III spectrin mutation L253P associated with spinocerebellar ataxia type 5 interferes with binding to Arp1 and protein trafficking from the Golgi. , 2010, Human molecular genetics.

[35]  M. Dutia,et al.  Loss of β-III Spectrin Leads to Purkinje Cell Dysfunction Recapitulating the Behavior and Neuropathology of Spinocerebellar Ataxia Type 5 in Humans , 2010, The Journal of Neuroscience.

[36]  R. Robledo,et al.  Targeted deletion of βIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes , 2010, Proceedings of the National Academy of Sciences.

[37]  J. Rothstein,et al.  Spectrin mutations cause spinocerebellar ataxia type 5 , 2006, Nature Genetics.

[38]  G. Appel,et al.  Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. , 2005, Journal of the American Society of Nephrology : JASN.

[39]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[40]  O. Ohara,et al.  Characterization of a new beta-spectrin gene which is predominantly expressed in brain. , 1998, Brain research. Molecular brain research.

[41]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.